A clinical trial of a potentially valuable medical treatment is planned.
It is unlikely that it will directly benefit the study subjects but very likely that it will benefit future patients.
There is a risk for short-term minor gastric discomfort but essentially no risk for long-term adverse effects.
The investigator concludes that disclosure of the risks may discourage participation in the trial.
Which of the following is the most appropriate next step?